Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile

• Published in: Journal of the American College of Cardiology 1999-04, Vol.33 (5), p.1294-1304
• Main Authors: Dangas, George, Badimon, Juan J, Smith, Donald A, Unger, Allen H, Levine, Daniel, Shao, John H, Meraj, Perwaiz, Fier, Carl, Fallon, John T, Ambrose, John A
• Format: Article
• Language: English
• Subjects: Aged; Aspirin - therapeutic use; Blood Coagulation Factors - metabolism; Cholesterol, LDL - blood; Coronary Thrombosis - blood; Coronary Thrombosis - drug therapy; Coronary Thrombosis - etiology; Double-Blind Method; Female; Fibrinolytic Agents - therapeutic use; Follow-Up Studies; Hemostasis - drug effects; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hyperlipidemias - blood; Hyperlipidemias - complications; Hyperlipidemias - drug therapy; Lipoprotein(a) - blood; Male; Middle Aged; Pravastatin - therapeutic use; Prospective Studies; Treatment Outcome
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/S0735-1097(99)00018-2

OBJECTIVES The study sought to determine the effects of lipid-lowering with pravastatin on the systemic fibrinolytic profile and on thrombus formation under dynamic flow conditions. BACKGROUND Lowering cholesterol (C) decreases clinical events in coronary artery disease (CAD) patients, but an analysis of the effects of lipid-lowering on the entire hemostatic and thrombotic profile has not been conducted. METHODS We prospectively studied 93 stable patients with untreated low-density lipoprotein cholesterol (LDL-C) >145 mg/dl. The CAD patients received pravastatin, and non-CAD patients were randomized to pravastatin versus placebo (double-blind). Thrombus formation upon an injured vascular surface was assessed in a substudy of 40 patients with a previously validated ex vivo perfusion chamber system. Systemic hemostatic markers and thrombus formation were evaluated at baseline, three and six months. RESULTS Placebo produced no changes in either the lipid profile, any of the hemostatic markers, or the ex vivo thrombus formation. Both pravastatin groups (CAD and non-CAD) showed decreased LDL-C by 30% within 6 weeks (188 to 126 mg/dl, p < 0.001 vs. baseline), and decreased plasminogen activator inhibitor-1 at 3- and 6-month follow-up compared to baseline (15% to 18% decrease at 3 months and 21% to 23% at 6 months). For the tissue plasminogen activator antigen, CAD and non-CAD groups showed significant decreases at 6 months compared to baseline (10% and 13%, respectively). No significant changes were observed with treatment in d-dimer, fibrinopeptide A, prothrombin fragment F1.2, factor VIIa, von Willebrand factor, or C-reactive protein. Fibrinogen levels were significantly increased at 6 months compared to baseline, though still below the upper normal limit. In the perfusion chamber substudy, there was a decrease in thrombus area in non-CAD patients treated with pravastatin at both 3 and 6 months compared to baseline (by 21% and 34%, respectively). The CAD patients showed decreases in thrombus formation by 13% at 3 months, and by 16% at 6 months. The change in LDL-C- correlated modestly with the change in thrombus formation (r = 0.49; p < 0.01). CONCLUSIONS Pravastatin therapy significantly decreased thrombus formation and improved the fibrinolytic profile in patients with and without CAD. These early effects may, in part, explain the benefit rendered in primary and secondary prevention of CAD.